Market Closed -
Nasdaq
04:00:00 2024-05-02 pm EDT
|
5-day change
|
1st Jan Change
|
4.96
USD
|
+0.20%
|
|
+2.69%
|
+14.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
340.9
|
408
|
124.3
|
196
|
206
|
238.8
|
-
|
-
|
Enterprise Value (EV)
1 |
324.2
|
412.9
|
158.3
|
196
|
206
|
238.8
|
238.8
|
238.8
|
P/E ratio
|
-4.49
x
|
-6.75
x
|
-4.22
x
|
-
|
9.62
x
|
19.2
x
|
29.3
x
|
33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.25
x
|
1.81
x
|
0.49
x
|
0.86
x
|
0.87
x
|
1.04
x
|
1.03
x
|
1
x
|
EV / Revenue
|
1.25
x
|
1.81
x
|
0.49
x
|
0.86
x
|
0.87
x
|
1.04
x
|
1.03
x
|
1
x
|
EV / EBITDA
|
-10,989,610
x
|
-20,028,600
x
|
10,455,282
x
|
6,009,876
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
15.4
x
|
561
x
|
6.02
x
|
-8.59
x
|
7.67
x
|
5.19
x
|
5.08
x
|
5.69
x
|
FCF Yield
|
6.47%
|
0.18%
|
16.6%
|
-11.6%
|
13%
|
19.3%
|
19.7%
|
17.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
38,961
|
39,762
|
40,886
|
46,346
|
47,571
|
48,239
|
-
|
-
|
Reference price
2 |
8.750
|
10.26
|
3.040
|
4.230
|
4.330
|
4.950
|
4.950
|
4.950
|
Announcement Date
|
2/20/20
|
2/25/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
272.3
|
225.1
|
253.2
|
228
|
235.6
|
230.6
|
232.6
|
239.8
|
EBITDA
|
-31.02
|
-20.37
|
11.89
|
32.62
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.1
|
-30.4
|
1.3
|
23.7
|
32.6
|
24.4
|
23.75
|
16
|
Operating Margin
|
-14.36%
|
-13.51%
|
0.51%
|
10.39%
|
13.84%
|
10.58%
|
10.21%
|
6.67%
|
Earnings before Tax (EBT)
1 |
-75.6
|
-59.8
|
-28.8
|
0.5
|
22.7
|
13.4
|
5.5
|
-15
|
Net income
1 |
-75.6
|
-60
|
-29.1
|
-
|
21.6
|
13.45
|
14.1
|
6.95
|
Net margin
|
-27.76%
|
-26.65%
|
-11.49%
|
-
|
9.17%
|
5.83%
|
6.06%
|
2.9%
|
EPS
2 |
-1.950
|
-1.520
|
-0.7200
|
-
|
0.4500
|
0.2583
|
0.1690
|
0.1500
|
Free Cash Flow
1 |
22.07
|
0.727
|
20.65
|
-22.83
|
26.87
|
46
|
47
|
42
|
FCF margin
|
8.11%
|
0.32%
|
8.16%
|
-10.01%
|
11.4%
|
19.95%
|
20.21%
|
17.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
173.7%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
124.39%
|
342.01%
|
333.33%
|
604.32%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
2/25/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
46.2
|
55.4
|
45.7
|
59.5
|
57.1
|
65.7
|
52.8
|
54.6
|
56.1
|
72.2
|
49.05
|
58.8
|
58.45
|
64.25
|
EBITDA
|
-
|
-
|
-
|
-
|
4.62
|
-
|
-
|
7.768
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9
|
6.8
|
-0.7
|
12.1
|
2.393
|
10
|
4.4
|
4.9
|
8.6
|
14.8
|
-7.7
|
8.9
|
9
|
14.2
|
Operating Margin
|
-19.48%
|
12.27%
|
-1.53%
|
20.34%
|
4.19%
|
15.22%
|
8.33%
|
8.97%
|
15.33%
|
20.5%
|
-15.7%
|
15.14%
|
15.4%
|
22.1%
|
Earnings before Tax (EBT)
1 |
-44.7
|
4.4
|
-3.4
|
9.5
|
-0.293
|
-5.3
|
1.6
|
2.3
|
6
|
12.8
|
-11.4
|
5.8
|
8.3
|
10.7
|
Net income
1 |
-44.7
|
4.2
|
-3.4
|
9.4
|
-0.36
|
-5.6
|
1.4
|
2.1
|
5.8
|
12.3
|
-10.2
|
6.15
|
6.2
|
11.25
|
Net margin
|
-96.75%
|
7.58%
|
-7.44%
|
15.8%
|
-0.63%
|
-8.52%
|
2.65%
|
3.85%
|
10.34%
|
17.04%
|
-20.8%
|
10.46%
|
10.61%
|
17.51%
|
EPS
2 |
-1.090
|
0.1000
|
-0.0800
|
0.2100
|
-0.0100
|
-0.1200
|
0.0300
|
0.0500
|
0.1200
|
0.2600
|
-0.2167
|
0.0283
|
0.1360
|
0.2667
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/3/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
4.92
|
34
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
16.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.2416
x
|
2.857
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
22.1
|
0.73
|
20.7
|
-22.8
|
26.9
|
46
|
47
|
42
|
ROE (net income / shareholders' equity)
|
-292%
|
-1,042%
|
-
|
123%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-30.6%
|
-25%
|
-12.4%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
247
|
239.6
|
235.2
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
0.0200
|
0.5100
|
-0.3500
|
-
|
-
|
-
|
-
|
Capex
|
0.31
|
0.05
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.11%
|
0.02%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
2/25/21
|
3/3/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
4.95
USD Average target price
4.333
USD Spread / Average Target -12.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +14.55% | 239M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|